Myriad Applauds AACU Position Statement on Molecular Testing for Risk Stratification in Prostate Cancer - Nasdaq

Submitted by Anonymous (not verified) on Tue, 03/06/2018 - 12:09

Myriad Applauds AACU Position Statement on Molecular Testing for Risk Stratification in Prostate CancerNasdaqSALT LAKE CITY, March 06, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, announced today that the American Association of Clinical Urologists (AACU) have issued a position statement supporting ...and more »